Effects of Clopidogrel Added to Aspirin

Slides:



Advertisements
Similar presentations
ACTIVE Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Advertisements

Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
Jonathan A. Edlow, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
Consultant Neurologist,
Secondary prevention after a TIA or ischemic stroke.
Randomized, double-blind, multicenter, controlled trial.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Terutroban versus aspirin in Patients with Cerebral Ischaemic Events (PREFORM): a Randomized, Double- blind Parallel-group Trial Daniel Wells Mercer University.
Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.
PJ Devereaux, Population Health Research Institute, Hamilton, Canada on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Rikki Weems, PGY III August 20, 2015
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D.,
R3 JUNG Myounghwa/Prof.KIM Woo-Shik N Engl J Med 2012;366:
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Gunter Breithardt,
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Non–ST-Segment Elevation Acute Coronary.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
1 Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation R3 Dae Ho Kim / Prof. Jin Bae Kim N Engl J Med 2011; DOI: Manesh R. Patel, M.D.,
Dr. Quan, Dr. Mirhashemi, Dr. Chiang
Clinical Trial Commentary
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
The American College of Cardiology Presented by Dr. Adnan Kastrati
Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
HOPE: Heart Outcomes Prevention Evaluation study
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Verstovsek S et al. Proc ASH 2011;Abstract 793.
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
First time a CETP inhibitor shows reduction of serious CV events
Oral Anticoagulation and Preventing Stent Thrombosis
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S
Jeff Macemon Waikato Cardiothoracic Unit
The following slides highlight a discussion and analysis of presentations in the Late-Breaking Clinical Trials session from the 55th Annual Scientific.
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
Dabigatran in myocardial injury after noncardiac surgery
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
NOACS: Emerging data in ACS/IHD
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
Dr. PJ Devereaux on behalf of POISE Investigators
Dabigatran in myocardial injury after noncardiac surgery
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?
Dabigatran in myocardial injury after noncardiac surgery
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter 
Section C: Clinical trial update: Oral antiplatelet therapy
Presenter Disclosure Information
Presentation transcript:

Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke Oscar R. Benavente, University of British Columbia, Vancouver, Canada; Robert G. Hart, Population Health Research Institute, Hamilton, ON, Canada; Leslie A. McClure and Jeffrey M. Szychowski, University of Alabama at Birmingham, Birmingham; Christopher S. Coffey, N Engl J Med 2012;367:817-825 R3 Kim seung min / Prof. Kim Woo-Shik Good morning. The journal that I’m going to present deals with the study about Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis My name is ko weonjin, my modulator is prof. 조경삼

Background small subcortical brain infarcts, commonly known as lacunar strokes, constitute about 25% of ischemic strokes This underlying disorder is the most frequent cause of covert brain infarcts and vascular cognitive impairment Lacunar infarcts are a frequent type of stroke caused mainly by cerebral small-vessel disease. The effectiveness of antiplatelet therapy for secondary prevention has not been defined Let me turn a page to introduce background - Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival - About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene that contributes to the pathophysiology of the disease - INCB018424 is a potent and selective JAK1 and JAK2 inhibitor common in elderly persons

Background Aspirin is accepted as standard antiplatelet therapy in patients with lacunar infarcts clopidogrel + aspirin has been shown to reduce the risk of stroke among patients with atrial fibrillation and those with acute coronary syndromes dual antiplatelet therapy has been associated with increased bleeding. The Secondary Prevention of Small Subcortical Strokes (SPS3) trial tested two randomized interventions, in a 2-by-2 factorial design Let me turn a page to introduce background - Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened survival - About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene that contributes to the pathophysiology of the disease - INCB018424 is a potent and selective JAK1 and JAK2 inhibitor common in elderly persons

Methods SPS3 was a randomized, multicenter clinical trial 82 clinical centers in North America, Latin America, and Spain double-blind, multicenter trial involving 3020 patients Recent symptomatic lacunar infarcts identified by magnetic resonance imaging. clopidogrel (75mg) + aspirin (35mg) VS placebo + aspirin (35mg) The primary outcome  recurrent stroke (ischemic stroke and intracranial hemorrhage) Let me show you the Method Patients 18 years of age or older with primary myelofibrosis were eligible for enrollment if they required therapy Additional eligibility criteria included ECOG performance status of 2 or less

Selection of Patients 30 years of age or older symptomatic lacunar stroke within the preceding 180 days not surgically amenable ipsilateral carotid artery disease Not cardio-embolic sources of stroke. meet MRI criteria lesion measuring 2.0 cm or less in diameter on DWI recent or remote cortical infarct, a large subcortical infarct , history of intracerebral hemorrhage were excluded Let me show you the Method Patients 18 years of age or older with primary myelofibrosis were eligible for enrollment if they required therapy Additional eligibility criteria included ECOG performance status of 2 or less

outcome primary hypothesis clopidogrel + aspirin would be superior to aspirin alone in reducing the primary outcome of stroke recurrence ? (ischemic stroke or intracranial hemorrhage) Ischemic stroke focal neurologic deficit of sudden onset persisting for >24 hours, without evidence of hemorrhage Secondary outcomes (acute myocardial infarction and death) vascular, nonvascular, or unknown cause. The primary safety outcome was major extracranial hemorrhage, they conducted a phase 1−2 trial in patients with JAK2 V617F−positive or JAK2 −negative primary myelofibrosis Patients were followed for a median of 14.7 months.

Result Now I’m going to show you some tables ,figures which is related results..

Between 2003 and 2011, a total of 3020 patients were enrolled in the study: 1503 in the group treated with aspirin plus placebo and 1517 in the group treated with aspirin plus clopidogrel. A total of 1960 of the participants (65%) were from North America, 694 (23%) from Latin America, and 366 (12%) from Spain. Participants had been followed for a mean of 3.4 years (range, 0 to 8.2) at the time of termination of the antiplatelet component of the study in August 2011 (see Fig. S1 in the Supplementary Appendix, available at NEJM.org)

The starting dose was 25 mg twice daily followed by escalation to 50 mg twice daily. Subsequently, once-daily doses were also evaluated, from 25 mg up to 200 mg once daily. In the phase 2 part of the study with defined enrollment targets and additional evaluations To identify an effective dosing schedule with a reduced incidence of thrombocytopenia. 25 mg twice daily, with a reduction to 10 mg twice daily after two cycles of therapy; 10 mg twice daily, with allowance for dose escalation after three cycles with allowance for dose increases up to 25 mg twice daily,

The starting dose was 25 mg twice daily followed by escalation to 50 mg twice daily. Subsequently, once-daily doses were also evaluated, from 25 mg up to 200 mg once daily. In the phase 2 part of the study with defined enrollment targets and additional evaluations To identify an effective dosing schedule with a reduced incidence of thrombocytopenia. 25 mg twice daily, with a reduction to 10 mg twice daily after two cycles of therapy; 10 mg twice daily, with allowance for dose escalation after three cycles with allowance for dose increases up to 25 mg twice daily,

The starting dose was 25 mg twice daily followed by escalation to 50 mg twice daily. Subsequently, once-daily doses were also evaluated, from 25 mg up to 200 mg once daily. In the phase 2 part of the study with defined enrollment targets and additional evaluations To identify an effective dosing schedule with a reduced incidence of thrombocytopenia. 25 mg twice daily, with a reduction to 10 mg twice daily after two cycles of therapy; 10 mg twice daily, with allowance for dose escalation after three cycles with allowance for dose increases up to 25 mg twice daily,

The starting dose was 25 mg twice daily followed by escalation to 50 mg twice daily. Subsequently, once-daily doses were also evaluated, from 25 mg up to 200 mg once daily. In the phase 2 part of the study with defined enrollment targets and additional evaluations To identify an effective dosing schedule with a reduced incidence of thrombocytopenia. 25 mg twice daily, with a reduction to 10 mg twice daily after two cycles of therapy; 10 mg twice daily, with allowance for dose escalation after three cycles with allowance for dose increases up to 25 mg twice daily,

Conclusion the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke among patients with recent lacunar strokes the addition of clopidogrel to aspirin did significantly increase the risk of bleeding and death among patients with recent lacunar strokes A post hoc subgroup analysis showed that the proportion of patients with a response in the pooled groups of patients who received 15 mg and 25 mg was similar among the 61 patients